Search results
Showing 331 to 345 of 1044 results for criteria
In development [GID-TA11288] Expected publication date: 23 April 2025
This indicator covers the contractor establishing and maintaining a register of patients with hypothyroidism who are currently treated with levothyroxine. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM99.
Evidence summaries: new medicines – Integrated process statement (PMG11)
Evidence summaries: new medicines – Integrated process statement
Infliximab for the treatment of adults with psoriasis (TA134)
Evidence-based recommendations on infliximab for treating severe psoriasis in adults.
Evidence-based recommendations on mepolizumab (Nucala) for treating severe eosinophilic asthma in adults.
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for untreated chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults.
Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)
This guideline covers diagnosing and managing chronic obstructive pulmonary disease or COPD (which includes emphysema and chronic bronchitis) in people aged 16 and older. It aims to help people with COPD to receive a diagnosis earlier so that they can benefit from treatments to reduce symptoms, improve quality of life and keep them healthy for longer.
Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults.
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)
Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy.
PredictSURE IBD and IBDX to guide treatment of Crohn's disease (DG45)
Evidence-based recommendations on PredictSURE IBD and IBDX for guiding treatment of Crohn’s disease
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)
Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs.
Borderline personality disorder: recognition and management (CG78)
This guideline covers recognising and managing borderline personality disorder. It aims to help people with borderline personality disorder to manage feelings of distress, anxiety, worthlessness and anger, and to maintain stable and close relationships with others.
This guideline covers diagnosing and managing hypertension (high blood pressure), including pre-eclampsia, during pregnancy, labour and birth. It also includes advice for women with hypertension who wish to conceive and women who have had a pregnancy complicated by hypertension. It aims to improve care during pregnancy, labour and birth for women and their babies.
Medical technologies evaluation programme methods guide (PMG33)
Medical technologies evaluation programme methods guide
Show all sections
- 1 Introduction
- 2 The medical technologies evaluation programme
- 3 Selecting and routing technologies
- 4 Principles for developing medical technologies guidance
- 5 Scope
- 6 Evidence and expert advice
- 7 Evidence synthesis and cost-consequence analysis
- 8 Evaluation of the evidence and decision-making by the committee